Group 1 - The company Langzi Co., Ltd. (SZ 002612) announced on August 1 that its fifth board meeting was held to review the proposal for amending the company's basic management system [1] - For the fiscal year 2024, the revenue composition of Langzi Co., Ltd. is as follows: Medical Aesthetics accounts for 48.92%, Fashion Women's Wear accounts for 33.83%, Green Baby Products accounts for 16.19%, and Other Businesses account for 1.06% [1]

Industry Overview - The medical beauty industry in China has developed rapidly despite its late start, with a comprehensive industry chain that includes upstream raw material suppliers and medical equipment providers, midstream public and private institutions, and downstream consumers [1][2]. Key Players - Major upstream raw material manufacturers include Huaxi Biological, Aimeike, Haohai Biological, Huadong Pharmaceutical, and Jiao Dian Biological, while medical equipment is primarily supplied by foreign leading manufacturers [2]. - Midstream medical institutions consist of well-known entities such as Huahan Plastic Surgery, Lido Plastic Surgery, and Ruile Medical, along with emerging platforms like Xinyang and Gem [2]. Regional Distribution - The coastal regions of China have a dense distribution of representative enterprises in the medical beauty industry, with significant concentrations in Beijing, Shanghai, and Guangzhou, which are home to top research institutions and production companies [5]. - These regions attract numerous renowned medical beauty hospitals and clinics, providing comprehensive and high-quality services to consumers [5]. Business Layout of Representative Companies - Companies like Aimeike and Huaxi Biological focus on domestic sales, while others like Langzi and Huahan have diversified regional strategies across various provinces [7]. - Some companies specialize in product development, while others emphasize service delivery, with notable examples including Aimeike and Haohai focusing on product R&D, and Aoyuan Meigu's strong hospital brand image [7]. Financial Performance - Aimeike reported a medical beauty business revenue of 3.023 billion yuan, with a business proportion of 99.90%, indicating a strong focus on medical devices [8]. - Huadong Pharmaceutical generated 2.041 billion yuan from its medical beauty segment, accounting for 4.87% of its total business [9]. Investment Trends and Future Plans - Companies are actively expanding their business layouts with a trend towards diversification and internationalization, such as Aimeike's acquisition of a Korean company and Haohai's collaboration with a U.S. firm for product innovation [10][11]. - Huadong Pharmaceutical is expanding its medical beauty business through acquisitions and partnerships, while Huaxi Biological is investing in new technologies and products [10][11].

Core Points - From January 1, 2026, foreign tourists in South Korea will no longer be able to apply for tax refunds on medical beauty services, as the government has decided not to extend the special VAT refund policy for foreign tourists, which will officially expire on December 31 of this year [1] - The South Korean government implemented a temporary VAT refund policy for medical beauty services in April 2016 to promote high-value medical tourism related to the Korean Wave, allowing foreign tourists to claim a 10% VAT refund when receiving services at designated medical institutions [1] - In 2024, it is estimated that 1.17 million foreign patients will visit South Korea for medical treatment, with a total medical expenditure of 1.41 trillion KRW, averaging about 1.53 million KRW per person [1] - The medical beauty tax refund applications have reached 1.01 million, with a total refund amount of 95.5 billion KRW [1] - The medical and tourism industries in South Korea are calling for the government to extend the tax refund policy, as the "cost-performance" advantage of the medical beauty industry is seen as a core competitive strength to attract foreign visitors [1] Industry Concerns - There are concerns that the lack of institutional incentives may lead some institutions and customers to evade taxes through cash transactions, resulting in regulatory difficulties and transparency issues [2] - The Ministry of Health and Welfare plans to negotiate with tax authorities to seek an extension of the temporary policy, leaving room for potential adjustments [2]

Core Viewpoint - The "Third China Plastic Surgery Innovation Transformation Competition" is officially launched at the first Global Aesthetic Medicine Technology Conference, emphasizing the theme "Technology Leads Aesthetics, Innovation Drives the Future" [3]. Group 1: Competition Overview - The competition is organized by Beijing Ba Da Chu Plastic Surgery Medical Technology Group Co., Ltd. and Zhongguancun Medical Device Park Co., Ltd. [3]. - Joint guiding units include several prestigious medical institutions such as the Chinese Academy of Medical Sciences Plastic Surgery Hospital and Peking Union Medical College Hospital [3]. Group 2: Competition Structure - Each sub-competition area will have an academic leader as the chair, responsible for forming the corresponding committee and expert panel [6]. - The sub-competition committees will include 1-2 members from the main competition committee [6]. Group 3: Sub-Competition Areas - The competition is divided into five sub-competition areas: East, South, West, North, and Central, covering various provinces [7]. Group 4: Participation Requirements - Participants must be from medical institutions, universities, or innovative enterprises in the aesthetic medicine field [22]. - Projects must focus on plastic surgery, medical aesthetics, or related biomedical fields, demonstrating significant innovation and clear commercialization potential [22]. Group 5: Evaluation Mechanism - The evaluation committee will consist of clinical experts (60%) and transformation experts (40%) [22]. - Evaluation criteria include innovation, technical feasibility, market prospects, team capability, and transformation potential, with varying weightings assigned to each criterion [23]. Group 6: Awards and Schedule - Awards include one first prize, two second prizes, three third prizes, and several excellence awards [25]. - The competition schedule includes a registration phase from June 10 to August 31, 2025, followed by preliminary evaluations and finals [25][26].

Core Viewpoint - The South Korean government has decided to cancel the 10% value-added tax refund policy for medical beauty services starting next year, which may negatively impact the influx of foreign tourists seeking these services [1] Group 1: Policy Changes - The tax refund policy was implemented in April 2016 to promote tourism and attract foreign visitors for medical beauty treatments [1] - Initially intended to last for one year, the policy has been extended multiple times since its inception [1] Group 2: Industry Concerns - Industry insiders express concerns that the cancellation of the tax refund may lead to a decrease in foreign tourists coming to South Korea for medical beauty services [1] - There is a potential risk that some medical institutions may resort to cash transactions with customers, creating a gray area in the industry [1]

Core Viewpoint - AirSculpt Technologies reported a decline in revenue and case volume in Q2 FY2025, but management remains optimistic about achieving its full-year guidance despite ongoing challenges in demand and performance [1][12]. Financial Performance - GAAP revenue for Q2 FY2025 was $44.0 million, down 13.7% year-over-year and below analyst expectations of $45.45 million [1][5]. - Diluted EPS was a loss of $0.01, an improvement from a loss of $0.06 in Q2 2024, but below the expected $0.01 [1][2]. - Adjusted EBITDA decreased to $5.8 million from $6.9 million in the same quarter last year, reflecting a 15.0% decline [1][2]. - Case volume fell to 3,392, a 14.1% decrease from the previous year [2][5]. - Adjusted net income was $1.2 million, down 76.8% from $5.1 million in Q2 2024 [2]. Business Overview - AirSculpt Technologies specializes in minimally invasive body contouring procedures, known for avoiding needles and scalpels, appealing to patients seeking less downtime [3]. - The company operates 32 centers in affluent regions across the U.S., Canada, and the UK, focusing on performance, marketing, and innovation [4]. Operational Highlights - The company noted incremental operational progress, with improvements in revenue decline percentages compared to Q1 FY2025 [1][5]. - Average revenue per case remained steady at approximately $12,975, maintaining the company's premium pricing [5]. - Same-center case volume fell 22.0% in Q2 FY2025, indicating challenges in older locations despite overall company growth [10]. Strategic Initiatives - AirSculpt is piloting new offerings, including a standalone skin tightening procedure and expanded consumer financing options [7]. - The company reported a record increase in patient leads, although conversion rates to booked procedures remain slow [8][9]. Financial Management - Long-term debt was reduced by $16 million during Q2 FY2025, with $8.2 million in cash and no outstanding line of credit, enhancing balance sheet strength [11]. - Operating cash flow for the first half of 2025 was $5.9 million, down from $6.8 million in the same period of 2024 [11]. Future Guidance - The company maintained its full-year 2025 revenue guidance of $160 million to $170 million and adjusted EBITDA target of $16 million to $18 million [12]. - Management expressed cautious optimism about achieving annual guidance, contingent on improvements in case volume and lead conversion [12].

企业名称上海瑷皙医疗美容门诊部有限公司法定代表人雷云芝注册资本300万人民币国标行业卫生和社 会工作>卫生>医院地址中国（上海）自由贸易试验区浦东大道720、728号L207、L214、L215、L216单 元企业类型有限责任公司（自然人投资或控股的法人独资）营业期限2025-8-1至无固定期限登记机关自 由贸易试验区市场监管局 来源：金融界 天眼查App显示，近日，上海瑷皙医疗美容门诊部有限公司成立，法定代表人为雷云芝，注册资本300 万人民币，由上海瑷菲秀管理咨询有限公司全资持股。 序号股东名称持股比例1上海瑷菲秀管理咨询有限公司100% 经营范围含许可项目：医疗服务；医疗美容服务。（依法须经批准的项目，经相关部门批准后方可开展 经营活动，具体经营项目以相关部门批准文件或许可证件为准）软件开发；第二类医疗器械销售。（除 依法须经批准的项目外，凭营业执照依法自主开展经营活动）自主展示（特色）项目：信息咨询服务 （不含许可类信息咨询服务）；企业管理咨询；市场营销策划；企业形象策划；会议及展览服务；健康 咨询服务（不含诊疗服务）；互联网销售（除销售需要许可的商品）；消毒剂销售（不含危险化学 品）；化妆品零售；化 ...

证券之星消息，8月1日医疗美容板块较上一交易日上涨0.06%，*ST美谷领涨。当日上证指数报收于 3559.95，下跌0.37%。深证成指报收于10991.32，下跌0.17%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 000615 | *ST美谷 | 3.12 | 2.30% | 11.73万 | 3619.67万 | | 688363 | 华熙生物 | 56'15 | 0.25% | 3.01万 | 1.57 Z | | 300896 | 爱美客 | 184.53 | -0.20% | 2.32万 | 4.31亿 | | 832982 | 锦波生物 | 322.91 | -3.46% | 1.04万 | 3.39亿 | 从资金流向上来看，当日医疗美容板块主力资金净流出1180.44万元，游资资金净流入977.47万元，散户 资金净流入202.97万元。医疗美容板块个股资金流向见下表： | 代码 | | | 名称 主力净流入（元） 主力净占比 游资净流入（元 ...

| 代码 | | | 名称 | | | | | --- | --- | --- | --- | --- | --- | --- | | 000615 *ST美谷 | 214.37万 | 7.42% | -53.63万 | -1.86% | -160.74万 | -5.57% | | 688363 华熙生物 | -420.73万 | -2.05% | 659.31万 | 3.22% | -238.58万 | -1.16% | | 300896 爱美客 | -7982.73万 | -13.22% | 2959.66万 | 4.90% | 5023.07万 | 8.32% | | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 000615 | *ST美谷 | 3.05 | 1.33% | 9.42万 | 2888.14万 | | 832982 | 锦波生物 | 334.50 | -0.26% | 6835.71 | 2.28亿 | | 688363 | 华熙生物 | 51.82 | -2.04% | 3 ...

7月31日，医疗美容概念上涨0.43%，今日主力资金流入2.44亿元，概念股24只上涨，46只下跌。 主力资金净流入居前的分别为安科生物（4.03亿元）、常山药业（2.5亿元）、汉商集团（1.1亿元）、 乐普医疗（6230.96万元）、振东制药（4677.6万元）。 序号代码名称最新价涨跌幅主力净流入主力净占比1300009安科生物12.1120.024.03亿元10.5%2300255常 山药业42.33.172.50亿元9.44%3600774汉商集团11.3310.01.10亿元40.97%4300003乐普医疗 15.560.846230.96万元5.49%5300158振东制药8.6216.644677.60万元2.15%6300238冠昊生物 17.41.163491.91万元8.34%7300753爱朋医疗31.397.283162.54万元5.27%8000725京东方Ａ4.04- 0.982808.99万元1.6%9000935四川双马19.550.572758.18万元9.8%10300244迪安诊断16.11.582710.14万元 4.4% 来源：金融界 ...